SMTL ID : 3vhe.1

Crystal structure of human VEGFR2 kinase domain with a novel pyrrolopyrimidine inhibitor.

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 1.55 Å

Oligo State

monomer

Ligands

1 x 42Q: 1-{2-fluoro-4-[(5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)oxy]phenyl}-3-[3-(trifluoromethyl)phenyl]urea(Non-covalent)

42Q.1: 20 residues within 4Å: Chain A: L.30, V.38, A.56, K.58, E.75, I.78, L.79, V.88, V.89, V.106, E.107, F.108, C.109, L.209, H.216, L.225, I.234, C.235, D.236, F.237 15 PLIP interactions: 15 interactions with chain A Hydrophobic interactions: A:L.30, A:V.38, A:E.75, A:I.78, A:L.79, A:V.89, A:V.106, A:F.108, A:D.236 Hydrogen bonds: A:K.58, A:E.75, A:E.75, A:E.75, A:C.109, A:D.236

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Oguro, Y. et al., Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation. Bioorg.Med.Chem. (2010)

Release Date

2011-11-02

Peptides

Vascular endothelial growth factor receptor 2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Vascular endothelial growth factor receptor 2